Table 3.
Absorption of anti-PCNA with 50 mM of purified full-length or truncated rPCNA proteins in patients with SLE, chronic HBV and HCV infection.
| Anti-PCNA after absorption (OD) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Patients | WT | WT | TR1 | TR2 | TR3 | TL1 | TL2 | TL3* |
| SLE | ||||||||
| 1 | 2·629 | 0·327 (88) | 1·709 (35) | 1·605 (39) | 1·333 (49) | 1·422 (46) | 1·401 (45) | 1·162 (39) |
| 2 | 1·485 | 0·401 (73) | 1·047 (29) | 0·988 (33) | 0·865 (41) | 0·891 (40) | 0·902 (39) | 1·002 (32) |
| 3 | 1·624 | 0·387 (76) | 1·233 (24) | 1·108 (32) | 0·872 (46) | 0·927 (43) | 1·123 (31) | 1·201 (26) |
| HBV | ||||||||
| 1 | 2·165 | 0·557 (74) | 2·025 (6) | 1·433 (34) | 0·956 (56) | 0·682 (68) | 0·801 (63) | 0·903 (58) |
| 2 | 1·920 | 0·583 (70) | 1·622 (15) | 1·409 (27) | 1·133 (41) | 0·833 (57) | 0·907 (53) | 0·945 (50) |
| 3 | 1·225 | 0·206 (83) | 1·088 (11) | 0·887 (28) | 0·656 (46) | 0·402 (67) | 0·502 (59) | 0·508 (59) |
| 4 | 1·860 | 0·496 (73) | 1·498 (19) | 1·222 (34) | 1·088 (41) | 0·912 (51) | 0·871 (53) | 1·027 (45) |
| 5 | 1·735 | 0·326 (81) | 1·104 (36) | 0·785 (55) | 0·563 (68) | 0·424 (75) | 0·496 (71) | 0·489 (72) |
| 6 | 3·011 | 0·318 (90) | 2·556 (15) | 1·862 (38) | 1·714 (43) | 1·002 (67) | 1·187 (60) | 1·282 (57) |
| HCV | ||||||||
| 1 | 1·548 | 0·387 (75) | 1·204 (22) | 0·928 (40) | 1·002 (35) | 0·889 (43) | 1·121 (28) | 1·014 (34) |
| 2 | 1·954 | 0·299 (85) | 1·638 (17) | 1·146 (41) | 1·098 (44) | 1·078 (45) | 1·153 (41) | 1·199 (39) |
| 3 | 1·714 | 0·412 (76) | 1·241 (28) | 1·272 (26) | 0·998 (42) | 0·883 (48) | 1·029 (40) | 1·229 (28) |
| 4 | 1·708 | 0·158 (91) | 1·328 (19) | 1·198 (30) | 1·020 (40) | 0·949 (44) | 0·998 (42) | 1·397 (18) |
| 5 | 2·105 | 0·598 (72) | 1·689 (20) | 1·301 (38) | 1·217 (42) | 1·424 (32) | 1·397 (34) | 1·388 (34) |
Numbers in parentheses are percentages of binding inhibition.
*
The average values of binding inhibition by TL3 in patients with SLE, chronic HBV and HCV infection were 32%, 58%, and 30%, respectively.